Table 1 Clinical characteristics of patients on DAPT with ticagrelor and clopidogrel stratified by diabetes status
Characteristic | Type 2 diabetes | No diabetes | pa | ||
|---|---|---|---|---|---|
Ticagrelor n = 30 | Clopidogrel n = 31 | Ticagrelor n = 32 | Clopidogrel n = 33 | ||
Age (years) | 66 ± 9 | 67 ± 10 | 63 ± 10 | 63 ± 9 | n.s |
Men/Women, n (%) | 22/8 (73/27) | 22/9 (71/29) | 24/8 (75/25) | 24/9 (73/27) | n.s |
Hypertension, n (%) | 27 (90) | 29 (94) | 26 (81) | 27 (82) | n.s |
Current smoking, n (%) | 7 (23) | 8 (26) | 10 (31) | 10 (30) | n.s |
Body-mass index (kg/m2) | 30.5 ± 3.8 | 29.5 ± 4.0 | 29.2 ± 2.7 | 28.4 ± 3.4 | n.s |
eGFR (mL/min / 1.73 m2) | 75 ± 17 | 74 ± 18 | 80 ± 19 | 78 ± 17 | n.s |
LDL cholesterol (mmol/L) | 2.0 ± 0.9 | 1.7 ± 0.8 | 1.9 ± 0.8 | 1.9 ± 0.9 | n.s |
C-reactive protein (mg/L) | 2.3 [1.3–3.6] | 2.5 [1.3–3.9] | 2.0 [1.2–3.1] | 2.2 [1.2–3.4] | n.s |
Triglycerides (mmol/L) | 1.7 ± 0.6 | 1.9 ± 0.7 | 1.5 ± 0.7 | 1.6 ± 0.7 | n.s |
Multivessel CAD, n (%) | 22 (73) | 24 (77) | 20 (63) | 21 (64) | n.s |
Left ventricular EF (%) | 50 ± 10 | 50 ± 9 | 53 ± 10 | 51 ± 11 | n.s |
Glycated hemoglobin (%) | 7.3 ± 1.0 | 7.3 ± 0.9 | n.d | n.d | n.s |
Years from DM diagnosis | 5 [3–10] | 6 [3–11] | n.a | n.a | n.s |
Drugs beyond DAPT, ACEI (or ARB), statin and PPI, n (%) | Â | Â | Â | Â | Â |
 Beta-blockers | 28 (93) | 30 (97) | 29 (91) | 28 (85) | n.s |
 Diuretics | 12 (40) | 10 (32) | 9 (28) | 10 (30) | n.s |
 Calcium channel blockers | 11 (37) | 12 (39) | 9 (28) | 11 (33) | n.s |
 Metformin | 28 (93) | 28 (90) | n.a | n.a | n.s |
 Sulfonyloureas | 7 (23) | 7 (23) | n.a | n.a | n.s |
 Insulin | 8 (27) | 10 (32) | n.a | n.a | n.s |